AnalystsSilvan TuerkcanSilvan Tuerkcan's Stock Forecasts
AnalystsSilvan Tuerkcan
Analyst Ranking
Top 17%
#847 out of 5081 analysts
Average Return
+4.45%
Win Rate
46%85 out of 184
Risk vs Reward
Poor
Good
Silvan Tuerkcan's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Intellia Therapeutics IncNTLA | +352.88% | $13.35 | $60.46 | 2020-02-27 - 2021-02-26 | Buy |
Logicbio Therapeutics IncLOGC2 | +345.16% | $0.47 | $2.07 | 2022-05-09 - 2022-11-15 | Buy |
Taysha Gene Therapies IncTSHA | +296.41% | $0.72 | $2.87 | 2023-03-29 - 2024-03-28 | Buy |
Benitec Biopharma IncBNTC | +290.63% | $2.88 | $11.25 | 2024-02-14 - 2025-02-14 | Buy |
Prime Medicine IncPRME | +286.38% | $1.18 | $4.54 | 2025-05-19 - 2025-10-29 | Buy |
Silvan Tuerkcan Analyst Color
Get additional color on Silvan Tuerkcan's coverage of popular stocks
Silvan Tuerkcan's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Intellia Therapeutics IncNTLA | 9 | Buy | $29.00 | +121.04% | Maintains | 2 days ago |
Terns Pharmaceuticals IncTERN | 13 | Buy | $15.00 | +87.03% | Maintains | 7 days ago |
Benitec Biopharma IncBNTC | 13 | Buy | $20.00 | +23.69% | Reiterates | a month ago |
Jasper Therapeutics IncJSPR | 7 | Buy | $6.00 | +154.24% | Maintains | a month ago |
Phreesia IncPHR | 1 | Buy | $34.00 | +46.43% | Maintains | 2 months ago |
Ideaya Biosciences IncIDYA | 2 | Buy | $45.00 | +39.84% | Maintains | 2 months ago |
Exelixis IncEXEL | 21 | Buy | $50.00 | +26.81% | Reiterates | 3 months ago |
Crispr Therapeutics AgCRSP | 15 | Buy | $86.00 | +37.47% | Reiterates | 4 months ago |
Nuvation Bio IncNUVB | 3 | Buy | $6.00 | +14.07% | Reiterates | 4 months ago |
Solid Biosciences IncSLDB | 3 | Buy | $15.00 | +173.22% | Reiterates | 5 months ago |
Taysha Gene Therapies IncTSHA | 13 | Buy | $6.00 | +19.76% | Maintains | 5 months ago |
Prime Medicine IncPRME | 3 | Buy | $6.00 | +32.16% | Maintains | 5 months ago |
Foghorn Therapeutics IncFHTX | 3 | Buy | $9.00 | +112.77% | Reiterates | 6 months ago |
Vor Biopharma IncVOR | 12 | Hold | $120.00 | +370.59% | Downgrades | 6 months ago |
Engene Holdings IncENGN | 4 | Buy | $18.00 | +147.70% | Reiterates | 6 months ago |
Acrivon Therapeutics IncACRV | 5 | Buy | $17.00 | +799.47% | Reiterates | 7 months ago |
Elevation Oncology IncELEV | 7 | Hold | $7.00 | +1,817.81% | Downgrades | 7 months ago |
Context Therapeutics IncCNTX | 1 | Buy | $4.00 | +247.83% | Initiates Coverage On | 10 months ago |
Relay Therapeutics IncRLAY | 10 | Buy | $21.00 | +187.28% | Reiterates | a year ago |
Macrogenics IncMGNX | 10 | Buy | $8.00 | N/A | Maintains | a year ago |
Cellectis SaCLLS | 6 | Buy | $6.00 | N/A | Reiterates | a year ago |
Notable Labs LtdNTBLQ | 3 | Buy | $9.00 | N/A | Reiterates | 2 years ago |
Mondaycom LtdMNDY | 3 | Buy | $280.00 | N/A | Maintains | 2 years ago |
Mirati Therapeutics IncMRTX | 8 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Generation Bio CoGBIO | 6 | Buy | $70.00 | N/A | Reiterates | 3 years ago |
Two Harbors Investment CorpTWO | 1 | Buy | $18.00 | N/A | Maintains | 3 years ago |
Logicbio Therapeutics IncLOGC2 | 3 | Buy | $3.00 | N/A | Maintains | 3 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Constellation Pharmaceuticals IncCNST | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Seagen IncSGEN | 2 | Buy | $200.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.